Skip to main content
Erschienen in: Obesity Surgery 6/2021

Open Access 10.02.2021 | Letter to the Editor

Immediate Euglycemic Diabetic Ketoacidosis After Gastric Bypass in a Patient with Type II Diabetes

verfasst von: Yu-Ting Lo, Kai-Hua Chen, Po-Chih Chang

Erschienen in: Obesity Surgery | Ausgabe 6/2021

download
DOWNLOAD
print
DRUCKEN
insite
SUCHEN
Hinweise

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Bariatric surgery has been proven to be an effective solution for morbid obesity with type 2 diabetes mellitus (T2DM), and such patients usually receive oral hypoglycemia agents or insulin for blood sugar control prior to surgery [1]. Though the occurrence of euglycemic diabetic ketoacidosis (DKA) is not clinically infrequent especially for those on treatment with sodium-glucose cotransporter 2 (SGLT2) inhibitor, reports of DKA after bariatric surgery are limited and most of the available reports discussed type I diabetes [13].
Herein, we report a T2DM patient (without SGLT2 inhibitor use) who developed euglycemic DKA soon after Roux-en-Y gastric bypass (RYGB). Moreover, the postoperative course was complicated with an attack of chronic gouty arthritis and acute exacerbation of chronic kidney disease, but eventually the patient made a full recovery.
A 52-year-old, morbidly obese male patient (body weight 110.3 kg; body mass index 37.7 kg/m2), with newly diagnosed T2DM (glycated hemoglobin 9.5%; homeostatic model assessment of insulin resistance 8.2) and poly-morbidities (hypertension, dyslipidemia, hyperuricemia with left ankle tophi, chronic kidney disease, and non-alcoholic fatty liver disease), was referred to our hospital for weight loss surgery. For blood sugar control, only metformin was prescribed (500 mg thrice a day) instead of a SGLT2 inhibitor. The patient had also taken diclofenac occasionally to relieve pain from chronic gouty arthritis over the bilateral feet. Laparoscopic RYGB was uneventfully performed on the 2nd day after admission with an estimated blood loss of 30 mL. The operation time was 210 min, and the intra-abdominal pressure of the pneumoperitoneum was up to 15–17 mmHg during the surgery.
On postoperative day 1, the patient started sipping water without obvious discomfort, and regular insulin was continuously infused at a rate of 1.25 U/h (blood sugar level was between 192 and 205 mg/dL) (Fig. 1). However, a spiking fever (39.3°C) occurred in the evening with a significant decrease in urine amount (from 3010 to 480 mL/day). Meanwhile, the patient also presented with tachypnea (26 breaths per minute) and tachycardia (123 beats per minute). No peritoneal sign or chest tightness was reported. The laboratory studies showed leukocytosis, elevated level of procalcitonin (3.4 ng/mL), and deteriorated renal function (creatinine 3.99 mg/L) (Table 1). Moreover, the blood gas analysis demonstrated metabolic acidosis with respiratory compensation (Table 1). The blood sugar still remained at a marginally higher level (219 mg/dL). Upon arriving at the intensive care unit, hypotension developed (72/49 mmHg) and fluid resuscitation, vasopressor, and empirical antibiotics (imipenem + cilastatin) were administered for possible occult intra-abdominal infection.
Table 1
Laboratory studies from postoperative day 1 to day 5. pH potential of hydrogen, pCO2 partial pressure of carbon dioxide, BUN blood urea nitrogen, eGFR estimated glomerular filtration rate
 
POD1
 
POD2
 
POD3
POD4
POD5
Serum glucose level (mg/dL)
205
219
296
371
359
404
212
pH
 
7.322
7.304
7.386
7.4
7.38
7.415
pCO2 (mmHg)
 
32.6
28.6
35.9
43
42
45.5
Bicarbonate (mmol/L)
 
16.5
13.9
21.1
26
24.3
28.5
Anion gap
   
19
  
10
Osmol (mOsm/kg)
   
317
   
Serum ketones (mmol/L)
  
6.1
4.3
0.7
  
White blood cell (/uL)
 
15,070
20,110
 
7660
4880
2900
Hemoglobin (g/dL)
 
13.8
12.5
 
34.9
35.3
34.7
Platelet (/uL)
 
182,000
201,000
 
134,000
119,000
135,000
Procalcitonin (ng/mL)
 
3.4
  
13.27
19.5
37.04
C-reactive protein (mg/L)
 
193.02
    
291.41
Lactate (mmol/L)
  
1.7
1.4
   
BUN (mg/dL)
26.3
27.7
30.8
34.5
34.9
35.3
34.7
Creatinine (mg/dL)
2.46
3.99
5.13
4.92
4.65
3.33
1.91
eGFR (mL/min/1.732)
27.66
15.83
11.83
12.42
13.27
19.5
37.04
On the following day (postoperative day 2), blood ketone levels were examined for fluctuating blood sugar levels, which disclosed a positive result (6.1 mmol/L) in favor of DKA. Regular insulin pump was titrated up to 2 U/h accordingly. Thereafter, the fever subsided and urine output increased gradually with concomitant recovery of blood pressure. Despite the occurrence of another episode of fever (38.3 °C) with significantly elevated procalcitonin (37.04 ng/mL) and C-reactive protein (291.41 mg/L) on postoperative day 5, in favor of a gout attack (blood uric acid 7.2 mg/dL), a non-enhanced abdominal computed tomography (CT) was still arranged in order to detect possible occult intra-abdominal infection or anastomotic leak. CT demonstrated neither fluid accumulation nor pneumoperitoneum. Therefore, the patient was immediately started with clear liquid diet and shifted to a full liquid diet on postoperative day 8 with the basal-bolus regular insulin regimen.
On postoperative day 10, we discontinued antibiotic use after the C-reactive protein and procalcitonin levels returned to the normal. His blood sugar remained stable after titration of insulin and oral hypoglycemic agent according to the endocrinologist’s suggestion. The patient was discharged on postoperative day 17. His renal function recovered gradually and no sequelae were noticed on 1-year follow-up.
High anion gap metabolic acidosis and ketonemia are the diagnostic adjuncts of DKA. While significant hyperglycemia (≥ 250 mg/dL) due to insulin deficiency remains the core etiology for this disease, mild hyperglycemia or even a euglycemic status could not completely exclude its clinical existence. DKA without marked hyperglycemia was defined as euglycemic DKA, which may manifest with subtle symptoms from dehydration and is usually induced by hyperglycemic status [1, 3].
Currently, one of the known risk factors for euglycemic DKA is the use of SGLT2 inhibitors. While the pathogenesis still remains unclear, excess urinary glucose excretion with relatively lower plasma glucose concentration may lead to an imbalance between insulin and glucagon (less insulin production from the beta cells, and further stimulation of the alpha cells). Moreover, the SGLT2 inhibitors can act independently on alpha cells with higher glucagon concentrations and eventually contribute to hepatic ketogenesis [38].
In an extensive review, most patients presenting with DKA after bariatric surgery were reported to have type 1 diabetes or were on treatment with SGLT2 inhibitors. This condition was extremely rare to be associated with T2DM morbidly obese patients or in the absence of SGLT2 inhibitor treatment [1]. General anesthesia, associated surgical stress, abrupt discontinuation of insulin, postoperative infection, prolonged starvation, poor oral intake, or severe dehydration may predispose DKA for those undergoing bariatric surgery [1, 7].
Moreover, DKA has been reported to usually present 1 to 6 weeks after the initial bariatric surgery among T2DM patients [2, 7]. Based on the similarity among manifestations of DKA and gastrointestinal symptoms due to bariatric surgeries, such as nausea or vomiting, timely identification and diagnosis may be difficult; nevertheless, our patient presented with euglycemic DKA sooner after initial RYGB (postoperative day 1), and the relative deficiency of insulin after this major surgery may be responsible for this condition. The recommendation of a basal insulin dosage of 0.3 U/kg of body weight during the perioperative stage as well as maintaining a target glucose level in the range of 140–180 mg/dL for the T2DM patients who will be undergoing bariatric surgery is essential [9]. In the early postoperative stage, diet modifications may be a key point for poor intake. Thus, dedicated titration of the insulin dose to avoid possible hypoglycemia is equally important [10].
Infection is another common predisposing factor for DKA, and procalcitonin can be a discriminatory biomarker for the detection of possible bacterial infection with concomitant leukocytosis and neutrophilia, which usually presents among those with DKA [2]. However, a previous case of a patient with DKA that had moderate elevation of procalcitonin without existing bacterial infection has been reported [11]. Furthermore, an acute attack of chronic gouty arthritis with febrile condition in our patient with concomitant euglycemic DKA could have been responsible for the relatively high procalcitonin level (37.04 ng/mL) [12, 13].
The rare occurrence of euglycemia DKA and complex manifestations of concurrent chronic kidney disease with acute exacerbation and a gout attack confused us during the first 3 days after initial RYGB. Though extremely rare, clinicians should not neglect the possibility of DKA for morbidly obese patients with T2DM after bariatric surgery, even with a euglycemic status and without a history of SGLT2 inhibitor treatment.

Acknowledgements

The authors would like to thank the enago (www.​enago.​tw) for their assistance with the language and grammar editing work.

Declarations

Conflict of Interest

The authors declare no competing interests.

Statement of Human and Animal Rights

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.
Informed consent was obtained from all individual participants included in the study.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://​creativecommons.​org/​licenses/​by/​4.​0/​.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Unsere Produktempfehlungen

Die Chirurgie

Print-Titel

Das Abo mit mehr Tiefe

Mit der Zeitschrift Die Chirurgie erhalten Sie zusätzlich Online-Zugriff auf weitere 43 chirurgische Fachzeitschriften, CME-Fortbildungen, Webinare, Vorbereitungskursen zur Facharztprüfung und die digitale Enzyklopädie e.Medpedia.

Bis 30. April 2024 bestellen und im ersten Jahr nur 199 € zahlen!

e.Med Interdisziplinär

Kombi-Abonnement

Für Ihren Erfolg in Klinik und Praxis - Die beste Hilfe in Ihrem Arbeitsalltag

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf SpringerMedizin.de.

Literatur
1.
Zurück zum Zitat Aminian A, Kashyap SR, Burguera B, et al. Incidence and clinical features of diabetic ketoacidosis after bariatric and metabolic surgery. Diabetes Care. 2016;39(4):e50–3.CrossRef Aminian A, Kashyap SR, Burguera B, et al. Incidence and clinical features of diabetic ketoacidosis after bariatric and metabolic surgery. Diabetes Care. 2016;39(4):e50–3.CrossRef
2.
Zurück zum Zitat Rizo IM, Apovian CM. Diabetic ketoacidosis post bariatric surgery. Front Endocrinol (Lausanne). 2018;9:812.CrossRef Rizo IM, Apovian CM. Diabetic ketoacidosis post bariatric surgery. Front Endocrinol (Lausanne). 2018;9:812.CrossRef
3.
Zurück zum Zitat Plewa MC, Bryant M, King-Thiele R. Euglycemic diabetic ketoacidosis. 2020 Apr 30. In: StatPearls. Treasure Island: StatPearls Publishing; 2020. Plewa MC, Bryant M, King-Thiele R. Euglycemic diabetic ketoacidosis. 2020 Apr 30. In: StatPearls. Treasure Island: StatPearls Publishing; 2020.
4.
Zurück zum Zitat Peters AL, Buschur EO, Buse JB, et al. Euglycemic diabetic ketoacidosis: a potential complication of treatment with sodium-glucose cotransporter 2 inhibition. Diabetes Care. 2015;38(9):1687–93.CrossRef Peters AL, Buschur EO, Buse JB, et al. Euglycemic diabetic ketoacidosis: a potential complication of treatment with sodium-glucose cotransporter 2 inhibition. Diabetes Care. 2015;38(9):1687–93.CrossRef
5.
Zurück zum Zitat Rosenstock J, Ferrannini E. Euglycemic diabetic ketoacidosis: a predictable, detectable, and preventable safety concern with SGLT2 inhibitors. Diabetes Care. 2015;38(9):1638–42.CrossRef Rosenstock J, Ferrannini E. Euglycemic diabetic ketoacidosis: a predictable, detectable, and preventable safety concern with SGLT2 inhibitors. Diabetes Care. 2015;38(9):1638–42.CrossRef
6.
Zurück zum Zitat Burke KR, Schumacher CA, Harpe SE. SGLT2 inhibitors: a systematic review of diabetic ketoacidosis and related risk factors in the primary literature. Pharmacotherapy. 2017;37(2):187–94.CrossRef Burke KR, Schumacher CA, Harpe SE. SGLT2 inhibitors: a systematic review of diabetic ketoacidosis and related risk factors in the primary literature. Pharmacotherapy. 2017;37(2):187–94.CrossRef
7.
Zurück zum Zitat Thiruvenkatarajan V, Meyer EJ, Nanjappa N, et al. Perioperative diabetic ketoacidosis associated with sodium-glucose co-transporter-2 inhibitors: a systematic review. Br J Anaesth. 2019;123(1):27–36.CrossRef Thiruvenkatarajan V, Meyer EJ, Nanjappa N, et al. Perioperative diabetic ketoacidosis associated with sodium-glucose co-transporter-2 inhibitors: a systematic review. Br J Anaesth. 2019;123(1):27–36.CrossRef
8.
Zurück zum Zitat Hoenes C, Rashid Q, Pimentel J. Diabetic ketoacidosis in a postoperative gastric bypass patient. J Surg Case Rep. 2017;2017(7):rjx148.CrossRef Hoenes C, Rashid Q, Pimentel J. Diabetic ketoacidosis in a postoperative gastric bypass patient. J Surg Case Rep. 2017;2017(7):rjx148.CrossRef
9.
Zurück zum Zitat Busetto L, Dicker D, Azran C, et al. Practical recommendations of the obesity management task force of the European Association for the study of obesity for the post-bariatric surgery medical management. Obes Facts. 2017;10(6):597–632.CrossRef Busetto L, Dicker D, Azran C, et al. Practical recommendations of the obesity management task force of the European Association for the study of obesity for the post-bariatric surgery medical management. Obes Facts. 2017;10(6):597–632.CrossRef
10.
Zurück zum Zitat Mulla CM, Baloch HM, Hafida S. Management of diabetes in patients undergoing bariatric surgery. Curr Diab Rep. 2019;19(11):112.CrossRef Mulla CM, Baloch HM, Hafida S. Management of diabetes in patients undergoing bariatric surgery. Curr Diab Rep. 2019;19(11):112.CrossRef
11.
Zurück zum Zitat Cipriano A, Rebelos E, Park N, et al. Moderate increase of serum levels of procalcitonin in diabetic ketoacidosis. Neth J Med. 2018;76(10):454.PubMed Cipriano A, Rebelos E, Park N, et al. Moderate increase of serum levels of procalcitonin in diabetic ketoacidosis. Neth J Med. 2018;76(10):454.PubMed
12.
Zurück zum Zitat Zhang J, Zhao C, Wu T, et al. Procalcitonin may not be a differential diagnostic marker for bacterial infection in febrile patients with chronic gouty arthritis. J Int Med Res. 2018;46(10):4197–206.CrossRef Zhang J, Zhao C, Wu T, et al. Procalcitonin may not be a differential diagnostic marker for bacterial infection in febrile patients with chronic gouty arthritis. J Int Med Res. 2018;46(10):4197–206.CrossRef
13.
Zurück zum Zitat Liu W, Sigdel KR, Wang Y, et al. High level serum procalcitonin associated gouty arthritis susceptibility: from a Southern Chinese Han population. PLoS One. 2015;10(7):e0132855.CrossRef Liu W, Sigdel KR, Wang Y, et al. High level serum procalcitonin associated gouty arthritis susceptibility: from a Southern Chinese Han population. PLoS One. 2015;10(7):e0132855.CrossRef
Metadaten
Titel
Immediate Euglycemic Diabetic Ketoacidosis After Gastric Bypass in a Patient with Type II Diabetes
verfasst von
Yu-Ting Lo
Kai-Hua Chen
Po-Chih Chang
Publikationsdatum
10.02.2021
Verlag
Springer US
Erschienen in
Obesity Surgery / Ausgabe 6/2021
Print ISSN: 0960-8923
Elektronische ISSN: 1708-0428
DOI
https://doi.org/10.1007/s11695-021-05263-7

Weitere Artikel der Ausgabe 6/2021

Obesity Surgery 6/2021 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

CME: 2 Punkte

Prof. Dr. med. Gregor Antoniadis Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

CME: 2 Punkte

Dr. med. Benjamin Meyknecht, PD Dr. med. Oliver Pieske Das Webinar S2e-Leitlinie „Distale Radiusfraktur“ beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

CME: 2 Punkte

Dr. med. Mihailo Andric
Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.